FIELD: microbiology; virology.
SUBSTANCE: disclosed is a method of identifying Arenaviridae family Arenavirus viruses by negative colonies damping reaction involving preparing a three-day monolayer of Vero B cells in plastic bottles; preparing dilutions of analyzed and control samples of arenaviruses; introducing into each of flasks 0.5 ml of the respective dilution, removal from the inoculant flasks after 60 min of incubation; primary agar coating preparation, containing by 0.1 % by volume of antibody-containing substrate, and its introduction into 8 ml into each bottle; preparing 0.1 % neutral red solution and staining cell monolayer 96 hours after applying the primary agar coating; taking into account the amount and determining the size of negative colonies formed by analyzed arenaviruses 24 hours after application of 0.1 % neutral red; calculating indices of the relative size of negative colonies and identifying the virus by reducing the size of negative colonies by at least 2-fold when the homologous virus-antibody pair interacts.
EFFECT: invention provides the possibility of identifying the analyzed arenavirus by adding 0_1 % (by volume) of the antibody-containing substrate to the primary agar coating, as well as reducing the analysis duration.
1 cl, 6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION OF AGAR COATINGS FOR DETERMINING MACHUPO - BOLIVIAN HEMORRHAGIC FEVER VIRUS POPULATION CONCENTRATION AND STRUCTURE WITH USING METHOD OF NEGATIVE COLONIES | 2014 |
|
RU2634868C2 |
STRAIN C/2014 OF MACHUPO VIRUS - AGENT OF BOLIVIAN HAEMORRHAGIC FEVER INTENDED FOR LABORATORY EVALUATION OF EFFECTIVENESS OF MEDICAL REMEDIES IN RESPECT OF THIS PATHOGEN | 2017 |
|
RU2699525C2 |
0 |
|
SU1778176A1 | |
METHOD OF VIRAL DISEASED DIAGNOSIS IN ANIMALS | 0 |
|
SU1797709A3 |
VIRUS LASS STRAIN "SVINKA" DESIGNATED FOR LABORATORY EVALUATION OF EFFECTIVENESS OF MEDICINAL PROTECTION AGENTS | 2004 |
|
RU2274655C1 |
AGAR OVERLAY MEDIUM FORMULATION APPLIED FOR NEGATIVE CLUMP TITRATION OF CORONAVIRUS - PATHOGENIC AGENT OF SERIOUS ACUTE RESPIRATORY SYNDROME | 2005 |
|
RU2325436C2 |
STRAIN O №2108/ZABAIKALSKY/2010 OF FOOT-AND-MOUTH DISEASE VIRUS Aphtae epizooticae OF TYPE O FOR MANUFACTURING BIOLOGICAL PREPARATIONS FOR DIAGNOSTICS OF FOOT-AND-MOUTH DISEASE VIRUS OF TYPE O | 2014 |
|
RU2575801C1 |
STRAIN O №2102/Zabaikalsky/2010 FMD VIRUS Aphtae epizooticae OF TYPE O FOR CONTROL OF ANTIGENIC AND IMMUNOGENIC ACTIVITY OF FMD VACCINES AND FOR PRODUCTION OF BIOLOGICAL PRODUCTS FOR DIAGNOSTICS AND SPECIFIC PROPHYLAXIS OF FMD OF TYPE O | 2014 |
|
RU2563522C1 |
METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
Authors
Dates
2020-08-04—Published
2018-06-26—Filed